We also found that a patient-derived tumour ex vivo culture with low BRCA1 and 53BP1 expression was resistant to olaparib or carboplatin but sensitive to ART558 (Fig. 3m, Supplementary Fig. 3k,l). Here, BRCA1 is linked to neoplasm.